Rare Frameshift Mutation Cys475Tyrfs(*)11 in the BCR/ABL Kinase Domain Contributes to Imatinib Mesylate Resistance in 2 Korean Patients with Chronic Myelogenous Leukemia

Ítems similars

• A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
  per: Park, Sang Hyuk, et al.
  Publicat: (2013)
• Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2(V617F) Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment
  per: Park, Sang Hyuk, et al.
  Publicat: (2013)
• Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
  per: Li, Yajuan, et al.
  Publicat: (2013)
• Phase I Trial of the Combination of Flavopiridol and Imatinib Mesylate in Patients with Bcr-Abl(+) Hematological Malignancies
  per: Bose, Prithviraj, et al.
  Publicat: (2012)
• ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB
  per: Constance, Jonathan E., et al.
  Publicat: (2012)